Limits...
The reduced predictive value of interleukin 28b gene polymorphisms in a cohort of patients with thyroiditis developed during antiviral therapy for chronic hepatitis C: a preliminary study.

Tran HA, Jones TL, Ianna EA, Gibson RA, Reeves GE - Hepat Mon (2012)

Bottom Line: Single nucleotide polymorphism in the interleukin28B (IL28B) gene was recently shown to be associated with a significant increase in response to interferon-α and ribavirin treatment in patients with chronic hepatitis C.Similarly, thyroid disease (TD) occurring during treatment confer an improved sustained virologic response (SVR).This suggests that TD in this clinical context may be a critical factor in the achievement of SVR, probably above that of the genetic predisposition.

View Article: PubMed Central - PubMed

Affiliation: Hunter Area Pathology Service, John Hunter Hospital, Newcastle, Australia.

ABSTRACT

Background: Single nucleotide polymorphism in the interleukin28B (IL28B) gene was recently shown to be associated with a significant increase in response to interferon-α and ribavirin treatment in patients with chronic hepatitis C. Similarly, thyroid disease (TD) occurring during treatment confer an improved sustained virologic response (SVR).

Objectives: To determine the role of IL28B genotypes in a cohort of hepatitis C patients who develop TD during treatment and its relationship to SVR.

Patients and methods: IL28B gene profiles including rs12979860, rs12980275 and rs 8099917 and their genotypes were determined in a cohort of 23 hepatitis C patients who developed TD during treatment and their relationship to SVR.

Results: Out of 23 studies cases, 19 has one or more favorable genotypes, of which 15 (78.9%) achieved SVR. Eleven has all three unfavorable genotypes and yet achieved 72.7 % SVR. The presence of more than one favorable genotype only correctly predicts SVR vs. non- SVR in ~50 % of cases, i.e. by chance.

Conclusions: Despite the small number of subjects, the presence of one or more unfavorable IL28B genotype does not portend a poor SVR prognostic outcome. This suggests that TD in this clinical context may be a critical factor in the achievement of SVR, probably above that of the genetic predisposition.

No MeSH data available.


Related in: MedlinePlus

Baseline Characteristics, Hepatitis Outcomes, Thyroid Functions and SNPs Profiles 23 Patients
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3475014&req=5

fig105: Baseline Characteristics, Hepatitis Outcomes, Thyroid Functions and SNPs Profiles 23 Patients

Mentions: Baseline characteristics of all 23 studied subjects are presented in Table 2 including the thyroid diagnoses and SNP genotypes. In this cohort, the most prevalent genotypes for rs12979860, rs12980275 and rs8099917 are CT (60.9 %), AG (56.5 %) and TT (52.2 %) respectively. Table 3 individualizes the various SNP genotype frequencies in our cohort and their relationships to SVR in all 23 subjects. These are compared with data from the literature (4, 6, 7) for the same genotypes in the HCV population. For rs12979860, genotype CC is least prevalent in the TD group, 17.4 % vs. 38.3 % while genotype TT appears similar although the data is inconsistent, 21.7 % vs. 13.6 % and 25.4 %. For rs12980275, AA is least frequent at 30.4 % vs. 40.2 %. The rest of the genotypes including SNP rs8099917 are similar in both cohorts of thyroid and non-thyroid HCV groups. Table 4 illustrates the number of individual favorable genotype in relation to SVR. As a favorable genotype is arbitrarily defined as > 50 %, this only applies to genotype CC in rs12979860, AA in rs12980275 and TT in rs8099917, Table 1. Nineteen out of 23 (82.6 %) has one be or more unfavorable genotypes of which 15 (78.9 %) achieve SVR. Eleven out of 23 (47.8 %) has all three unfavorable genotypes, yet achieving a 72.7 % SVR rate. Overall, 12 has 1, 7 has 2 and 4 has 3 favorable genotypes. A multivariate analysis indicates that the presence of more than one favorable genotype completely predicts SVR. One patient with one favorable genotype did not achieve SVR although the likelihood of response for that particular genotype (TT rs8099917) is only modest at 56 % (patient 12, Table 2). Overall, un invariant logistic regression analysis revealed no relationship between SVR and all variables displayed in Table 1. Subsequent multivariate analysis showed a similar lack of association.


The reduced predictive value of interleukin 28b gene polymorphisms in a cohort of patients with thyroiditis developed during antiviral therapy for chronic hepatitis C: a preliminary study.

Tran HA, Jones TL, Ianna EA, Gibson RA, Reeves GE - Hepat Mon (2012)

Baseline Characteristics, Hepatitis Outcomes, Thyroid Functions and SNPs Profiles 23 Patients
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3475014&req=5

fig105: Baseline Characteristics, Hepatitis Outcomes, Thyroid Functions and SNPs Profiles 23 Patients
Mentions: Baseline characteristics of all 23 studied subjects are presented in Table 2 including the thyroid diagnoses and SNP genotypes. In this cohort, the most prevalent genotypes for rs12979860, rs12980275 and rs8099917 are CT (60.9 %), AG (56.5 %) and TT (52.2 %) respectively. Table 3 individualizes the various SNP genotype frequencies in our cohort and their relationships to SVR in all 23 subjects. These are compared with data from the literature (4, 6, 7) for the same genotypes in the HCV population. For rs12979860, genotype CC is least prevalent in the TD group, 17.4 % vs. 38.3 % while genotype TT appears similar although the data is inconsistent, 21.7 % vs. 13.6 % and 25.4 %. For rs12980275, AA is least frequent at 30.4 % vs. 40.2 %. The rest of the genotypes including SNP rs8099917 are similar in both cohorts of thyroid and non-thyroid HCV groups. Table 4 illustrates the number of individual favorable genotype in relation to SVR. As a favorable genotype is arbitrarily defined as > 50 %, this only applies to genotype CC in rs12979860, AA in rs12980275 and TT in rs8099917, Table 1. Nineteen out of 23 (82.6 %) has one be or more unfavorable genotypes of which 15 (78.9 %) achieve SVR. Eleven out of 23 (47.8 %) has all three unfavorable genotypes, yet achieving a 72.7 % SVR rate. Overall, 12 has 1, 7 has 2 and 4 has 3 favorable genotypes. A multivariate analysis indicates that the presence of more than one favorable genotype completely predicts SVR. One patient with one favorable genotype did not achieve SVR although the likelihood of response for that particular genotype (TT rs8099917) is only modest at 56 % (patient 12, Table 2). Overall, un invariant logistic regression analysis revealed no relationship between SVR and all variables displayed in Table 1. Subsequent multivariate analysis showed a similar lack of association.

Bottom Line: Single nucleotide polymorphism in the interleukin28B (IL28B) gene was recently shown to be associated with a significant increase in response to interferon-α and ribavirin treatment in patients with chronic hepatitis C.Similarly, thyroid disease (TD) occurring during treatment confer an improved sustained virologic response (SVR).This suggests that TD in this clinical context may be a critical factor in the achievement of SVR, probably above that of the genetic predisposition.

View Article: PubMed Central - PubMed

Affiliation: Hunter Area Pathology Service, John Hunter Hospital, Newcastle, Australia.

ABSTRACT

Background: Single nucleotide polymorphism in the interleukin28B (IL28B) gene was recently shown to be associated with a significant increase in response to interferon-α and ribavirin treatment in patients with chronic hepatitis C. Similarly, thyroid disease (TD) occurring during treatment confer an improved sustained virologic response (SVR).

Objectives: To determine the role of IL28B genotypes in a cohort of hepatitis C patients who develop TD during treatment and its relationship to SVR.

Patients and methods: IL28B gene profiles including rs12979860, rs12980275 and rs 8099917 and their genotypes were determined in a cohort of 23 hepatitis C patients who developed TD during treatment and their relationship to SVR.

Results: Out of 23 studies cases, 19 has one or more favorable genotypes, of which 15 (78.9%) achieved SVR. Eleven has all three unfavorable genotypes and yet achieved 72.7 % SVR. The presence of more than one favorable genotype only correctly predicts SVR vs. non- SVR in ~50 % of cases, i.e. by chance.

Conclusions: Despite the small number of subjects, the presence of one or more unfavorable IL28B genotype does not portend a poor SVR prognostic outcome. This suggests that TD in this clinical context may be a critical factor in the achievement of SVR, probably above that of the genetic predisposition.

No MeSH data available.


Related in: MedlinePlus